Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 12/20 | 0.60 |
| ▸ | PGR | P06401 | 4/20 | 0.60 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 3/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | LIG1 | P18858 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3227855 | 1.00 | NR3C1 (0.60) | NR3C1PGRDAOL3MBTL1CES1 | |
| SCHEMBL3219690 | 0.81 | NR3C1 (0.66) | NR3C1PGRPARP1 | |
| SCHEMBL3231815 | 0.80 | NR3C1 (0.61) | NR3C1PGRL3MBTL1 | |
| SCHEMBL3222368 | 0.79 | NR3C1 (0.59) | NR3C1PGR | |
| SCHEMBL3231379 | 0.78 | NR3C1 (0.63) | NR3C1PGR | |
| SCHEMBL3233149 | 0.78 | NR3C1 (0.71) | NR3C1PGRL3MBTL1 | |
| SCHEMBL3226492 | 0.78 | NR3C1 (0.62) | NR3C1PGR | |
| SCHEMBL3228652 | 0.78 | NR3C1 (0.64) | NR3C1PGRPARP1 | |
| SCHEMBL3226272 | 0.78 | NR3C1 (0.59) | NR3C1PGRPARP1 | |
| SCHEMBL3231133 | 0.78 | NR3C1 (0.86) | NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116538-B1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-8367695-B2 | Condensed tetrahydroquinoline derivative and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100063055-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2116538-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063055-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | NR3C2, MC2R, NR5A1 | NR3C1 4/4885PGR 11/4885DAO 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.